Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
194
Active, not recruiting, industry sponsors, Hematology and blood cancers, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting411
- Completed1,472
194 trials
Showing 1 to 25, recently updated first.
- A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.Active, not recruiting
Shenzhen Fosun Kairos Biotechnology Co., Ltd.Industry
NCT07606937 · 12 participants (planned) · Start Apr 29, 2026 · Primary completion Nov 30, 2026
Drug: FKC876 injection · For: Relapsed/Refractory Large B-cell Lymphoma
Sites: Beijing, China; Guangzhou, China; Suzhou, China · 6 sites in all
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05397496 · 61 participants · Start Oct 3, 2022 · Primary completion May 31, 2027
Drug: PIT565 · For: B-cell Non-Hodgkin Lymphoma (B-NHL); B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Miami, Florida; Chicago, Illinois; Fairway, Kansas · 18 sites in all
- A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting ConditionsActive, not recruiting
Sichuan Huiyu Pharmaceutical Co., LtdIndustry
NCT07790562 · 88 participants (planned) · Start Jul 23, 2026 · Primary completion Sep 29, 2026
Drug: Ferric Derisomaltose Injection; Ferric Derisomaltose Injection [MonoFer®] · For: Iron Deficiency Anemia
Sites: Zhengzhou, China
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05169515 · 121 participants (planned) · Start Oct 26, 2022 · Primary completion Apr 30, 2029
Drug: SC Mosunetuzumab; IV Glofitamab and 4 more · For: Non-Hodgkin Lymphoma
Sites: San Francisco, California; Aurora, Colorado; Tampa, Florida · 24 sites in all
- A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaActive, not recruiting
TakedaTakeda (TAK)
NCT02979522 · 59 participants · Start Sep 6, 2017 · Primary completion May 5, 2020
Drug: Brentuximab vedotin; Doxorubicin and 2 more · For: Hodgkin Disease
Sites: Aurora, Colorado; Cincinnati, Ohio; Salvador, Brazil · 14 sites in all
- Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple MyelomaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04091126 · 118 participants · Start Dec 18, 2019 · Primary completion Jun 2, 2025
Drug: Belantamab mafodotin; Bortezomib and 2 more · For: Multiple Myeloma
Sites: Westwood, Kansas; Charlotte, North Carolina; Madison, Wisconsin · 30 sites in all
- Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Active, not recruiting
Cellectis S.A.Industry
NCT04150497 · 45 participants · Start Oct 14, 2019 · Primary completion Sep 16, 2026
Drug: UCART22; CLLS52 · For: B-cell Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 20 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04077723 · 498 participants (planned) · Start Aug 13, 2019 · Primary completion Dec 28, 2026
Drug: Englumafusp alfa; Obinutuzumab and 2 more · For: Lymphoma, Non-Hodgkin
Sites: Pasadena, California; San Francisco, California; St Louis, Missouri · 35 sites in all
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04925479 · 46 participants · Start Dec 27, 2021 · Primary completion Sep 3, 2027
Drug: Asciminib Pediatric formulation group; Asciminib Adult formulation group · For: Myeloid Leukemia, Philadelphia Positive
Sites: Indianapolis, Indiana; Boston, Massachusetts; New York, New York · 23 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05646836 · 90 participants (planned) · Start Mar 21, 2023 · Primary completion Nov 18, 2026
Drug: Cevostamab; XmAb24306 and 1 more · For: Multiple Myeloma
Sites: Adelaide, Australia; Melbourne, Australia; Vejle, Denmark · 13 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05828511 · 148 participants · Start Dec 19, 2023 · Primary completion Nov 2, 2035
Drug: Linvoseltamab · For: Multiple Myeloma
Sites: Los Angeles, California; Orange, California; Denver, Colorado · 32 sites in all
- Study of Oral MRT-2359 in Selected Cancer PatientsActive, not recruiting
Monte Rosa Therapeutics, IncIndustry
NCT05546268 · 174 participants (planned) · Start Oct 12, 2022 · Primary completion Dec 2026
Drug: Oral MRT-2359; Oral MRT-2359 and 4 more · For: NSCLC; SCLC; High Grade Neuroendocrine Cancer and 5 more
Sites: Scottsdale, Arizona; San Diego, California; New Haven, Connecticut · 17 sites in all
- A Rollover Study of CC-122Active, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05688475 · 12 participants (planned) · Start Apr 11, 2023 · Primary completion Nov 30, 2026
Drug: CC-122; Dexamethasone · For: Non-Hodgkin Lymphoma
Sites: New York, New York; Nashville, Tennessee; Madison, Wisconsin · 7 sites in all
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05753501 · 135 participants · Start Jun 9, 2023 · Primary completion Mar 2031
Drug: ABBV-101 · For: Hematologic Cancer
Sites: Tucson, Arizona; Orange, California; Palo Alto, California · 51 sites in all
GenmabIndustry
NCT05201248 · 49 participants · Start Mar 10, 2022 · Primary completion Oct 2027
Drug: Epcoritamab; Cyclophosphamide and 5 more · For: B-Cell Non-Hodgkin Lymphoma
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 18 sites in all
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruiting
GenmabIndustry
NCT03625037 · 666 participants · Start Jun 26, 2018 · Primary completion Jan 2029
Drug: Epcoritamab · For: DLBCL; High-grade B-cell Lymphoma (HGBCL); Primary Mediastinal Large B-cell Lymphoma (PMBCL) and 6 more
Sites: Phoenix, Arizona; San Francisco, California; Denver, Colorado · 85 sites in all
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeActive, not recruiting
GenmabIndustry
NCT04623541 · 194 participants · Start Nov 25, 2020 · Primary completion Dec 2027
Drug: Epcoritamab; Epcoritamab and 7 more · For: Relapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome and 1 more
Sites: Birmingham, Alabama; California City, California; Duarte, California · 81 sites in all
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruiting
GenmabIndustry
NCT04542824 · 78 participants · Start Aug 20, 2020 · Primary completion Sep 2027
Drug: Epcoritamab (monotherapy); Epcoritamab and 4 more · For: Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma and 3 more
Sites: Sendai, Japan; Aichi, Japan; Chiba, Japan · 15 sites in all
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03399799 · 279 participants · Start Dec 16, 2017 · Primary completion Jul 7, 2022
Drug: Talquetamab · For: Hematological Malignancies
Sites: Birmingham, Alabama; Duarte, California; Aurora, Colorado · 13 sites in all
- A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Active, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05784441 · 21 participants · Start Nov 6, 2023 · Primary completion Jan 6, 2027
Drug: JNJ-90009530 · For: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Sites: Iowa City, Iowa; Lexington, Kentucky; Rochester, Minnesota · 15 sites in all
- A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)Active, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06660563 · 19 participants · Start Oct 22, 2024 · Primary completion Jan 19, 2026
Drug: JNJ-80948543; JNJ-75348780 · For: Lymphoma, Non-Hodgkin
Sites: Concord, Australia; Fitzroy, Australia; North Ryde, Australia · 11 sites in all
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04722146 · 140 participants · Start Mar 12, 2021 · Primary completion Oct 3, 2025
Drug: Teclistamab; Daratumumab and 4 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; San Francisco, California; Denver, Colorado · 27 sites in all
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruiting
GenmabIndustry
NCT04663347 · 543 participants · Start Nov 3, 2020 · Primary completion Sep 30, 2027
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; rituximab and lenalidomide and 16 more · For: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 57 sites in all
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05421663 · 166 participants · Start Aug 12, 2022 · Primary completion Jul 30, 2041
Drug: JNJ-90014496 · For: Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
Sites: Duarte, California; Denver, Colorado; Iowa City, Iowa · 32 sites in all
- A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04108195 · 290 participants · Start Feb 21, 2020 · Primary completion Apr 7, 2027
Drug: Daratumumab; Talquetamab and 2 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; San Francisco, California · 24 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.